Imatinib mesylate (Gleevec® USA; Glivec-Europe/Australia; formerly STI571) is a BCR-ABL TKI which has intensely improved the treatment outcomes in chronic-phase CML patients (CML-CP). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.